By enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying, these drugs create a multifaceted approach to managing blood sugar levels and reducing appetite
Results from the SURPASS program's phase 3 trials indicate that tirzepatide, administered weekly in doses of 5mg, 10mg, and 15mg, significantly enhances glycemic control in T2D
ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes
Phase 2 data suggests retatrutide may produce greater weight reduction than currently approved agents, but its long-term safety profile has not been fully established, and no head-to-head regulatory-grade trials have been completed
Nothing here is medical, dosing, or therapeutic guidance